October 18, 2024
2 min watch
Save
VIDEO: IOL-based bimatoprost implant shows ‘remarkable’ results at 18 months
Issue: December 25, 2024
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Patrick Mooney, CEO of Spyglass Pharma, discusses the company’s IOL-based bimatoprost drug delivery platform for patients with open-angle glaucoma or ocular hypertension.
Mooney shared 18-month follow-up data from a study of 23 patients with ocular hypertension or open-angle glaucoma who also had a visually significant cataract.
“The results are remarkable,” he said. “Mean IOP reduction across all three groups was 43.7%, and 100% of patients remain off of all topical IOP-lowering therapy.”
Published by:
Sources/Disclosures
Collapse
Source:
Mooney P. AAO 2024 glaucoma/digital showcase. Presented at: Eyecelerator@AAO; Oct. 17, 2024; Chicago.
Disclosures:
Mooney reports being CEO of Spyglass Pharma.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.